- | Fountain Therapeutics
Fountain’s William Greene is Striving to Extend Human Health Span
What it means to age is changing, and William Greene, M.D., CEO of Fountain Therapeutics, is one of those driving the change. Rather than focusing primarily on lifespan, he and his company are focusing on healthspan, and in particular, the impact of chronic degenerative diseases. The goal is to restore cellular resilience.
- | DURECT
Episode 21-37 One-way streets in Pompeii ???
On this week’s Tech Nation, from the bumpy history of the chariot to how smartphones are essential equipment for transportation in the future. Economist deputy editor Tom Standage talks about “A Brief History of Motion: From the Wheel, to the Car, to What Comes Next”. Then Dr. Jim Brown, the CEO of DURECT, describes their first Phase 2 clinical trials for Alcoholic Hepatitis, known as AH. And a look at what comes next for their approach to regenerative medicine.
- | Portage
iNK T-Cell Immuno-oncology For Solid Tumors With Dr. Ian Walters
Dr. Ian Walters’ company, Portage Biotech, is focused on addressing the 75% of cancer patients who show no, or limited, response to existing therapies such as checkpoint inhibitors. Leading that charge are the company’s invariant natural killer T cell agonists, designed to activate the innate and adaptive immune system, as well as a growing portfolio of proteins, antibodies, and small molecules. On this episode of the Business of Biotech, Dr. Walters shares what’s fueling the company’s progress, including its unique financing strategy and its approach to de-risking platform development for novel immuno-oncology therapies.
- | Clene Nanomedicine
Going for gold: Clene ups nanocatalysis capacity to support ALS lead
Clene Nanomedicine has quadrupled production capacity to support candidate CNM-Au8, a gold nanocrystal suspension it says could be a gamechanger in the neurodegenerative disease space.
- | AltruBio
Companies To Watch: AltruBio
AltruBio is a private company developing checkpoint-regulator monoclonal antibodies (mAbs) for treating immune disorders. The company uses its checkpoint regulators in a way it believes down-modulates overactivated
- | Heat Biologics
Morrisville firm looking to fight next pandemic
Even as the world battles the coronavirus pandemic, Jeff Wolf, CEO of Morrisville-based Heat Biologics, says his company is studying potential vaccines to limit potential future viral pandemics.
- | Heat Biologics
CDC, Heat Biologics Establish New Pandemic Preparedness Initiatives
North Carolina-based Heat Biologics is also taking a proactive stance against potential pandemic threats. This week, the company established its Biothreat Advisory Board. Heat Chief Executive Officer Jeff Wolf said the board was created to support its biosecurity/biodefense initiative, which was originally conceived as a result of the ongoing pandemic.
- | BeyondSpring Pharmaceuticals
Playing a surprisingly hot hand, BeyondSpring nails a $200M China deal in wake of a pivotal success
BeyondSpring announced this morning a commercialization and co-development agreement between its Chinese subsidiary Wanchunbulin and China’s Jiangsu Hengrui Pharmaceuticals.
